Drugs / CMTS1215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07556276 | Mar 2025 → Dec 2030 expected | cancer | The Second Hospital of Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMTS1215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07556276 ↗ |
| Modality | Other / unclassified | “CMTS1215 (Proteus mirabilis) oncolytic bacteria injection” NCT07556276 ↗ |
| Route | Intravenous | “intratumoral injection (under direct visualization or endoscopic guidance) or intravenous injection” NCT07556276 ↗ |